In recent months, demand for GLP1 (glucagon like peptide 1) receptor agonists has skyrocketed across the country, leaving providers inundated with prescription requests and patients frustrated with shortages. GLP1 agonists have an important place in obesity therapy. However, there are many unanswered questions about long-term side effects, cost-effectiveness and the duration of therapy. Unfortunately, current manufacturing cannot adequately meet the demand for both diabetes and obesity treatment. The VHAN Pharmacy Team has the following recommendations for navigating ongoing shortages.